Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Cancer type

Gastroesophageal

Gastric and esophageal cancer.

Must-know

  1. 1

    ctDNA in esophageal adenocarcinoma

    Cabalag et al. Annals of Surgery. 2022.

    ctDNA was assessed against CT and PET for prognosis, response to neoadjuvant therapy, and surveillance for recurrence in esophageal adenocarcinoma.

    PMID 35737908DOI

A randomized ctDNA-guided gastroesophageal trial was not identified.

Listed when a study is a randomized or prospective interventional ctDNA or MRD trial, is cited in NCCN or ESMO guidance, or is a prospective validation cohort in a high-impact journal. Shorter lists mean fewer studies met that rule. No test is ranked.

Publications and presentations

Accruing studies for Gastroesophageal